Determining fluorescence Limit of Detection with Nanoparticle Tracking Analysis (NTA)

Similar documents
Direct visualization, sizing and concentration measurement of fluorescently labeled nanoparticles using NTA

Adeno-Associated Virus titer and aggregation characterization

Differentiation and characterization of subvisible particulates in therapeutic protein products

Characterization of IgG monomers & their aggregates

Five compelling reasons to replace sieve analysis with laser diffraction

Monitoring Microfiltration Processes for Water Treatment

Particle size analysis of cement using the technique of laser diffraction

Visualisation, Sizing and Counting of Fluorescent and Fluorescently-Labelled Nanoparticles

AlphaLISA C-tag Acceptor Beads

Anti-V5 AlphaLISA Acceptor Beads

RHEOLOGICAL PROPERTIES ROSAND RH2000 RHEOLOGICAL INSTRUMENTS BACKED WITH RHEOLOGICAL EXPERIENCE

ab CFSE Fluorescent Cell Labeling Kit

RHEOLOGICAL PROPERTIES ROSAND RH7 & RH10 RHEOLOGICAL INSTRUMENTS BACKED WITH RHEOLOGICAL EXPERIENCE

ab CFSE Fluorescent Cell Labeling Kit

LANCE Ultra Cortisol Detection Kit

Optimizing Rheology for Paint and Coating Applications

Size quality report for the Zetasizer Nano

E. COLI HOST CELL PROTEIN ELISA KIT ASSAY PRINCIPLE PRODUCT MANUAL HCP-002 E. COLI HOST CELL PROTEIN ELISA KIT KIT INCLUDES

Accelerating the development of optimized therapeutic protein formulations using Differential Scanning Calorimetry

LANCE Ultra Lambda Light Chain (Human) Detection Kit

Research Reagents. Anti-Mouse IgG Acceptor Beads

Anti-6xHis AlphaLISA Acceptor Beads

LANCE Ultra Kappa Light Chain (Human) Detection Kit

Anti-6xHis AlphaLISA Acceptor Beads

ExoGlow -NTA Fluorescent Labeling Kit

Supporting Information. A Real-Time Surface Enhanced Raman Spectroscopy Study of Plasmonic Photothermal Cell Death Using Targeted Gold Nanoparticles

Working Reagent Preparation 1:1,000 dilution in standard Alcoholic Ortho- Phosphoric acid staining solution

IMAP TR-FRET Phosphodiesterase Evaluation Assay Kit With Progressive Binding System Quantity: 800 test points (20 L reactions)

PRODUCT DATA SHEET. Carboxylated Fluorescent Gold Nanoparticles. Description. Characteristics

Histone H4 Biochemical AlphaLISA Immunoassay Kit

Flow Cytometry - The Essentials

PRODUCT DATA SHEET. Carboxylated Gold Nanoparticles. Description. Features. Storage. Applications. Handling. Characteristics

Live and Dead Cell Assay

MST Starting Guide Monolith NT.115

Product Information FluoroStain DNA Fluorescent Staining Dye (Green, 10,000X)

Human Immunoglobulin E (IgE) LANCE Ultra Detection Kit

Drug Discovery Research Clinical Screening. Comparison of ELISA and AlphaScreen Assay Technologies for Measurement of Protein Expression Levels

EGF and EGFR (Human) Binding LANCE Ultra Kit

MICROCAL PEAQ-DSC BIOMOLECULAR STABILITY ANALYSIS FOR THE REGULATED ENVIRONMENT LABEL-FREE ANALYSIS MICROCALORIMETRY

CBI Toolbox Tour 2015

SURFACE ENHANCED RAMAN SCATTERING NANOPARTICLES AS AN ALTERNATIVE TO FLUORESCENT PROBES AN EVALUATION

Human Adiponectin Kit

LANCE Ultra IGF-1 (Rat) Detection Kit

High-throughput automation with the Attune NxT Autosampler: consistent results across all wells and across plates

NV High Brightness Series

Chinese Hamster Ovary Cell Host Cell Proteins (CHO HCP) (broad reactivity) LANCE Ultra Detection kit

Human Transferrin LANCE Ultra Detection kit

Zenon Goat IgG Labeling Kits

Supplementary Figure 1. Binding capacity of the nanoparticles. Protein A-coated magnetic nanoparticles were mixed with FITC-antibody (antibody

Human C-Reactive Protein (CRP) LANCE Ultra Detection Kit

Separate and Quantify Rituximab Aggregates and Fragments with High-Resolution SEC

Human Interleukin 6 (hil6) LANCE Ultra Detection Kit

FluoVolt Membrane Potential Kit

Supplementary Figure 1. CryoTEM images of the barcoded nanoparticles (a) and

Human Albumin (halbumin) LANCE Ultra Detection Kit

AlphaLISA Laminin (Human) Detection Kit

ab Generic Caspase Activity Assay Kit Fluorometric Green

Human Insulin-like Growth Factor 1 (IGF1) LANCE Ultra Detection kit

Breast cancer 2 (BRCA2, Human) AlphaLISA Detection Kit

Human Vascular Endothelial Growth Factor (VEGF) LANCE Ultra Detection kit

Supplementary Figures and legend. Heparin affinity purification of extracellular vesicles.

AlphaLISA Hyaluronic Acid (human) Detection Kit

LANCE Ultra FCGR3A/CD16a (176Val/V158) Kit

BQC DCFH-DA ROS ASSAY KIT. KP test

Electronic Supplementary Information. Fibrillation Kinetics of Aβ(1-40) Peptide Depend on Surface Curvature at Nano-Bio Interfaces

BrdU Cell Proliferation ELISA

Product Information. Before you begin. Component A 1 vial of 30 ul vial of 300 ul each Glycerol. Tris

Rabbit Immunoglobulin G (rabigg) LANCE Ultra Detection kit

Direct visualization, sizing and concentration measurements of drug delivery nanoparticles using Nanoparticle Tracking Analysis (NTA)

LANCE Ultra MMP-7 (Human) Detection Kit

LANCE Ultra ApoE (Human) Detection Kit

CTLA-4 and CD86 (Human) Binding AlphaLISA Kit

Human Erythropoietin (EPO) kit

LANCE Ultra Fibronectin (Human) Detection Kit

Human Tumor Necrosis Factor-alpha (htnfα) LANCE Ultra Detection Kit

Human Interleukin 1 beta (hil1β) LANCE Ultra Detection Kit

Human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) LANCE Ultra Detection Kit

USER GUIDE. Introduction. Catalog No. C10423, C10723

Gyrolab ADA assay protocol

Bovine Immunoglobulin A (biga) AlphaLISA Detection Kit

Bovine Immunoglobulin A (biga) AlphaLISA Detection Kit

+ M III. IMAP Screening Express Kit Product #8073 Quantity: 8000, 20 µl reactions (80 µl final volumes) Low FP. M III High FP.

Mouse Immunoglobulin E (IgE isotyping) AlphaLISA Immunoassay Kit

Color-Rich Fluoro-Max Dyed Microparticles March 2008

USER GUIDE. Introduction. Catalog No. C10730, C10731

BIO BASIC INC. BRADFORD PROTEIN ASSAY KIT SK3031. Version 4.0 ISO9001 Certified

AlphaLISA Progesterone Detection Kit

ab MDR Assay Kit (Fluorometric)

ExoCap TM Streptavidin Kit

SpectraMax Quant AccuClear Nano

Human Receptor Tyrosine-Protein Kinase ErbB-2 (herbb2/her2) LANCE Ultra Detection kit

Transcription:

Determining fluorescence Limit of Detection with Nanoparticle Tracking Analysis (NTA) FLUORESCENCE DETECTION PARTICLE SIZE PARTICLE CONCENTRATION Introduction The ability to detect nanoparticle fluorescence is important when attempting to distinguish a particular subset of particles from within a complex background. Particles which are fluorescent can be measured in terms of particle size and concentration to understand the nature of those particles. A typical application for this is in understanding the fate of drug delivery vectors as well as understanding the toxicology of nanoparticles in biological environments. Alternatively, fluorescently labeled antibodies may be used to bind specifically to target particles within a sample, thus providing a mechanism to identify specific particle populations within an unknown sample. This has implications in diagnostic applications such as research into exosomes and microvesicles, where specific markers can be identified and monitored in the detection of disease. Nanoparticle Tracking Analysis (NTA), available on the NanoSight range of instruments, can operate in light scatter mode where all particles within a sample are visualized and measured (and thus does not require the sample to be fluorescently labeled to take a measurement). Alternatively, the instruments can also operate in fluorescence mode where only fluorescently labeled particles are detected and measured. The NanoSight system uses either a 405 nm (violet), 488 nm (blue) or 532 nm (green) laser source to excite particles labelled with appropriate fluorophores, whose fluorescence can then be determined using suitably matched long or short-pass filters. This application note works through an experiment to approximately establish a baseline in terms of the fluorescence limit of detection for a given fluorophore. The biotin-streptavidin interaction is known to be a very strong non-covalent binding interaction, K d ~10-14 mol/l. Each streptavidin molecule has 4 available Malvern Instruments Worldwide Sales and service centres in over 65 countries www.malvern.com/contact 2015 Malvern Instruments Limited

sites for biotin binding, one for each of the monomer units that comprise the quaternary structure. This ratio was used to calculate a maximum possible number of fluorescent streptavidin molecules that each gold nanoparticle could have bound to the surface (Figure 1). Figure 1: Graphic showing the formation of the strepatividn-biotin complex and it s binding to a gold nanoparticle Materials Nominally 80 nm spherical gold nanoparticles with biotin attached to the surface (GNP) were purchased from NanoPartz (product code C11-80-TB-50), with a specified biotin/particle density. The size of the particles was determined by DLS and TEM and was supplied at a concentration of approximately 9.4 x 10 11 particles/ml. Streptavidin (F*) fluorescently labelled with NorthernLights 557 dye was purchased from R&D Systems (product code NL999) at a stock concentration of 1 mg/ml (~10 16 particles/ml). This dye has an absorption peak at 557 nm and an emission peak of 574 nm. 2 Determining fluorescence Limit of Detection with Nanoparticle Tracking Analysis (NTA)

Methods A NanoSight LM10 system equipped with a 532 nm LM14 laser module, 565 nm long pass emission filter, high sensitivity (HS) scoms camera and NTA syringe pump were used for all data collection. Data were analyzed using NTA3.1 software. All dilutions were carried out in 0.02 μm filtered PBS. Firstly, an appropriate concentration of GNP for NTA was prepared by serial dilution. The GNP working stock was prepared by diluting the original sample by a factor of 100 in PBS. Aliquots of this stock along with F* were taken and diluted in PBS to give an overall sample volume between 1200-2000 µl and NP concentration of ~4 x 10 8 particles/ml. Samples were prepared such that F* was added at the ratio 0-1000000 F* per 1 GNP and mixed by pipetting. From preliminary experiments, and the knowledge that a stable biotin-streptavidin complex forms rapidly, each sample was allowed to incubate for 30 minutes in the dark prior to measurement at room temperature. The total concentration of particles under scatter and fluorescence was then measured using NTA. Camera settings were kept constant for measurement type one for all fluorescent measurements and another for all scatter measurements. The NTA syringe pump was used to ensure analysis under slow and constant flow was carried out in both scatter and fluorescence modes, allowing data from both modes to be compared directly. (N.B. Analysis in flow is necessary in fluorescence mode to prevent the fluorophore from photobleaching, and additionally improves the statistical robustness of the data by ensuring a greater proportion of the sample is measured). 3 videos of 60 seconds were captured for each sample under both the scatter and fluorescence mode. A number of controls were also measured as shown in Table 1. Table 1: Controls measured in both scatter mode and fluorescence mode, and their significance. Sample Scatter Mode Fluorescence Mode Biotin-gold nanoparticles Confirmation of concentration No signal expected Fluorescent streptavidin Checking for aggregates Checking for aggregates Biotin-Gold-nonfluorescent streptavidin Checking for aggregates No signal expected 3 Determining fluorescence Limit of Detection with Nanoparticle Tracking Analysis (NTA)

Assumptions and Caveats The nanoparticles were supplied with biotin specified as being 2 molecules per nm 2 of the particles surface. For an 80 nm spherical particle the amount of biotin was calculated as 40,000 biotin molecules per particle. A streptavidin molecule has 4 biotin binding sites, thus if all biotin molecules on each gold particles are bound ~10,000 streptavidin molecules would be required to fully cover the particle (100% coverage). When the nanoparticles are incubated with F* it is assumed that the F* is distributed homogeneously over all the nanoparticles present such that all particles have bound the same number of F* molecules. Results The gold nanoparticles were measured initially under both scatter and fluorescence modes under a constant flow of 50 a.u. The NTA size distribution profile of the particles is shown in Figure 2. Figure 2: Size distribution profile of gold-biotin nanoparticles measured under a constant flow of 50. Only data from light scatter mode are shown as the unlabelled particles did not exhibit a fluorescent signal. To find an appropriate incubation time a preliminary time course study was carried out. Nanoparticles were incubated with the equivalent of approximately 1000 F* molecules per nanoparticle and allowed to incubate at room temperature in the dark for different times. As shown in the Table 2, the labelling was nearly instant and a 30 minutes incubation was selected to ensure the incubation for binding biotin-streptavidin was complete. 4 Determining fluorescence Limit of Detection with Nanoparticle Tracking Analysis (NTA)

Table 2: Incubation time labelling efficiency data from biotin-gold NP labelled with F* in ratio of approximately 1000F* molecules to one gold NP. Time from labelling [minutes] 3 20 35 60 150 Fluorescence efficiency [%] 62 67 64 67 69 When different ratios of F* per gold nanoparticle were measured the percentage of the total population measured in fluorescence mode increased with increasing ratios of F* until 100% coverage was achieved. Selected ratio data are shown in Figure 3. Figure 3: Size distribution data for 10F* per 1GNP (green), 100F* per 1GNP (blue), 1000F* per 1GNP (red) and 10000F* per 1GNP (black) measured in fluorescence mode When increasing the ratio of F* beyond 100% coverage the number of particles measured in fluorescence mode decreased with increasing amounts of fluorescence. The image background became brighter making the particles more difficult to visualize and track with the NTA software. The overall proportion of fluorescently labelled particles measured in fluorescence mode NTA increased up to "100% coverage", whilst adding further fluorescence to the sample caused a decline in the number of particles measured Figure 4. 5 Determining fluorescence Limit of Detection with Nanoparticle Tracking Analysis (NTA)

Figure 4: Top) Size distribution data for 10000F* per 1GNP (zero excess fluorophore, green), 11000F per 1GNP (1.1x excess fluorophore, blue), 100000F* per 1GNP (10x excess fluorophore, red) and 1000000F* per 1GNP (100x excess fluorophore, black) measured in fluorescence mode. Bottom) Overall summary of fluorescently labelled GNP measured in fluorescence mode of NTA. The x axis shows the ratio of fluorescence molecules per GNP (Data combined from three separate assays). Conclusion This short study aims to look at the sensitivity of NTA in terms of measuring fluorescently labelled particles using standard materials with known affinity strengths. It makes a number of assumptions (gold particle surface area, biotin coverage, complete streptavidin binding, homogeneous sample incubations), but demonstrates that with an equivalence of 5 fluorescent streptavidin molecules per gold nanoparticle some gold particles are detected as being fluorescently labelled. There are a number of reasons why 100% recovery may not have been measured at this level: 1. These particles will be noticeably dimmer than those with greater loadings, therefore they may only be observed in a smaller scattering volume. 6 Determining fluorescence Limit of Detection with Nanoparticle Tracking Analysis (NTA)

2. Uneven loading of the particles, i.e. at the 5F/particle loading level, some particles may have 10F attached whereas others may have 0F attached. It may be that only the brighter particles are detectable. 3. Photo bleaching would have a greater effect on particles with a lower number of fluorophores than particles with a high number of fluorophores. In this example the particles with 5F* per gold nanoparticle were very dim and were challenging to visualize and focus in fluorescence mode in comparison to gold nanoparticles with 600F or more which were very bright in comparison. In addition, increasing the ratio of fluorescent molecules at a level greater than 10% above that of a theoretical 100% coverage gives rise to a raised unbound fluorescence background. This raised background makes particle visualization and tracking much more difficult and thus the number of particles measured decreases as the fluorescence excess increases. The titration of fluorophore to target nanoparticle is crucial to establish a labelling protocol that will lead to the high fluorescence signal detection. Having too few or too many fluorophore particles in the sample will affect the efficiency of the fluorescence measurement with NTA. Depending on the fluorophore used and its binding efficiency, the particle size and the laser wavelength, a recommended minimum number of 10 20 organic fluorophore molecules per nanoparticle will be required to successfully visualize, track and measure fluorescently labelled particles in fluorescence mode using NTA. 7 Determining fluorescence Limit of Detection with Nanoparticle Tracking Analysis (NTA)

Malvern Instruments Limited Grovewood Road, Malvern, Worcestershire, UK. WR14 1XZ Tel: +44 1684 892456 Fax: +44 1684 892789 www.malvern.com Malvern Instruments is part of Spectris plc, the Precision Instrumentation and Controls Company. Spectris and the Spectris logo are Trade Marks of Spectris plc. All information supplied within is correct at time of publication. Malvern Instruments pursues a policy of continual improvement due to technical development. We therefore reserve the right to deviate from information, descriptions, and specifications in this publication without notice. Malvern Instruments shall not be liable for errors contained herein or for incidental or consequential damages in connection with the furnishing, performance or use of this material. Malvern Instruments owns the following registered trademarks: Bohlin, FIPA, Insitec, ISYS, Kinexus, Malvern, Malvern 'Hills' logo, Mastersizer, MicroCal, Morphologi, Rosand, 'SEC-MALS', Viscosizer, Viscotek, Viscogel and Zetasizer. 2015 Malvern Instruments Limited AN150507FluorescenceLOD